Is this it?, page-8

A balanced post mighty pirate. The recent Nature publication is a big positive for the science, it is very difficult to be published in such a prestigious journal and the quality of the science must be exceptional to pass the peer review process. But you can't have your cake and eat it as well. If the quality of the MK science is so good, you have to ask yourself why has CDY been so spectacularly unsuccessful in selling it to investors? It's been over a year since the subsidiaries have been established and not a dime of smart money has been invested, indeed the MK programmes (apart from the R&D publications) have been stagnant for so long that it is not surprising that the market does not ascribe any value to these assets. The Evolis line could make a significant contribution to the CDY valuation, but the MK products seem to be hindering rather than helping any SP appreciation. There are examples of early stage biotechs which have attracted funding to get to the clinic so it is not too early. Either the science or commercial opportunity is too risky, or the investor pitch is inadequate.